Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement

Vankemmelbeke, Mireille; McIntosh, Richard S.; Chua, Jia Xin; Kirk, Thomas; Daniels, Ian; Patsalidou, Marilena; Moss, Robert; Parsons, Tina; Scott, David; Harris, Gemma; Ramage, Judith M.; Spendlove, Ian; Durrant, Lindy G.

doi:10.1158/0008-5472.CAN-19-3599

All Outputs (3)

Molecular and structural basis for Lewis glycan recognition by a cancer-targeting antibody (2020)
Journal Article

Immunotherapy has been successful in treating many tumour types. The development of additional tumour-antigen binding monoclonal antibodies (mAbs) will help expand the range of immunotherapeutic targets. Lewis histo-blood group and related glycans ar... Read More about Molecular and structural basis for Lewis glycan recognition by a cancer-targeting antibody.

Increased IL-2 and reduced tgf-? upon t-cell stimulation are associated with GM-CSF upregulation in multiple immune cell types in multiple sclerosis (2020)
Journal Article

© 2020 by the authors. Granulocyte macrophage colony stimulating factor (GM-CSF) is a pro-inflammatory cytokine produced by immune cells. Recent evidence suggests that GM-CSF plays an important role in multiple sclerosis (MS) pathogenesis. We investi... Read More about Increased IL-2 and reduced tgf-? upon t-cell stimulation are associated with GM-CSF upregulation in multiple immune cell types in multiple sclerosis.

Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement (2020)
Journal Article

©2020 American Association for Cancer Research. Murine IgG3 glycan-targeting mAb often induces direct cell killing in the absence of immune effector cells or complement via a proinflammatory mechanism resembling oncotic necrosis. This cancer cell kil... Read More about Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement.